An adaptive optimal design for the Emax model and its application in clinical trials

Journal of Biopharmaceutical Statistics

Volumn 19, Issue 2, 2009, Pages 360-385

  Leonov, Sergei ^a   Miller, Sam ^b  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Adaptive design; Constrained dose selection; Emax model; Optimal model based design; Unknown parameters in variance

Indexed keywords

ALGORITHM; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; EXPERIMENTAL DESIGN; EXPERIMENTAL MODEL; MATHEMATICAL MODEL; NONLINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; SIMULATION; STATISTICAL MODEL; STATISTICAL PARAMETERS;

ALGORITHMS; ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LOGISTIC MODELS; MODELS, STATISTICAL; NONLINEAR DYNAMICS; NOOTROPIC AGENTS; RESEARCH DESIGN;

EID: 60749097433     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400802677240     Document Type: Article

References (34)

1. Atkinson, A. C., Donev, A. (1992). Optimum Experimental Design. Oxford: Clarendon Press.
2. Atkinson, A. C., Cook, R. D. (1995). D-optimum designs for heteroscedastic linear models. JASA 90:204-212.
3. Bauer, P., Brannath, W. (2004). The advantages and disadvantages of adaptive designs in clinical trials. Drug Discov. Today 9:351-357.
4. Beal, S. L., Sheiner, L. B. (1988). Heteroscedastic nonlinear regression. Technometrics 30(3):327-338.
5. Box, G. E. P., Hunter, W. G. (1965). Sequential design of experiments for nonlinear models. In: Korth, J. J., ed. Proceedings of IBM Scientific Computing Symposium, White Plains: IBM, pp. 113-137.
6. Chaloner, K., Verdinelli, I. (1995). Bayesian experimental design: a review. Statistical Science 10:273-304.
7. Chernoff, H. (1953). Locally optimal designs for estimating parameters. Ann. Math. Stat. 24:586-602.
8. Downing, D. J., Fedorov, V. V., Leonov, S. L. (2001). Extracting information from the variance function: optimal design. In: Atkinson, A. C., Hackl, P., Müller, W. G., eds. MODA6 - Advances in Model-Oriented Design and Analysis. Heidelberg: Physica-Verlag, pp. 45-52.
9. Dragalin, V., Fedorov, V. V. (2006). Adaptive designs for dose-finding based on efficacy-toxicity response. J. Stat. Plann. Inf. 136:1800-1823.
10. max model. J. Biopharm. Statist. 18:1051-1070.
11. Fan, S. K., Chaloner, K. (2001). Optimal design for a continuation-ratio model. In: Atkinson, A. C., Hackl, P., Müller, W. G., eds. MODA6 - Advances in Model-Oriented Design and Analysis. Heidelberg: Physica-Verlag, pp. 77-85.
12. Fedorov, V. V. (1972). Theory of Optimal Experiment. New York: Academic Press.
13. Fedorov, V. V., Hackl, P. (1997). Model-Oriented Design of Experiments. New York: Springer.
14. Fedorov, V. V., Leonov, S. L. (2004). Parameter estimation for models with unknown parameters in variance. Comm. Stat. Theory and Methods 33(11):2627-2657.
15. Fedorov, V. V., Leonov, S. L. (2005). Response driven designs in drug development. In: Wong, W. K., Berger, M. P. F., eds. Applied Optimal Designs. Chichester: Wiley, pp. 103-136.
16. Fedorov, V. V., Gagnon, R. C., Leonov, S. L. (2002). Design of experiments with unknown parameters in variance. Appl. Stoch. Mod. Bus. Ind. 18:207-218.
17. Fedorov, V. V., Gagnon, R., Leonov, S., Wu, Y. (2007). Optimal design of experiments in pharmaceutical applications. In: Dmitrienko, A., Chuang-Stein, C., D'Agostino, R., eds. Pharmaceutical Statistics Using SAS: A Practical Guide. Cary: SAS Press, pp. 151-195.
18. Flournoy, N., Rosenberger, W. F., Wong, W. K. (eds.) (1998). New Developments and Applications in Experimental Design. Hayward: Institute of Mathematical Statistics, Lecture Notes, v. 34.
19. Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., Pinheiro, J. (2006). Adaptive designs in clinical drug development - an executive summary of the PhRMA Working Group. J. Biopharm. Stat. 16(3):275-283.
20. Haines, L. M., Perevozskaya, I., Rosenberger, W. F. (2003). Bayesian optimal designs for phase I clinical trials. Biometrics 59:561-570.
21. Hill, P. D. H. (1980). D-optimal designs for partially nonlinear regression models. Technometrics 22:275-276.
22. Huet, S., Bouvier, A., Poursat, M.-A., Jolivet, E. (2004). Statistical Tools for Nonlinear Regression. A Practical Guide with S-PLUS and R examples. New York: Springer.
23. Jennison, C., Turnbull, B. W. (2000). Group Sequential Methods with Applications to Clinical Trials. Boca Raton: Chapman & Hall.
24. Kiefer, J., Wolfowitz, J. (1960). The equivalence of two extremum problems. Canad. J. Math. 12:363-366.
25. Magnus, J. R., Neudecker, H. (1988). Matrix Differential Calculus with Applications in Statistics and Econometrics. New York: Wiley.
26. Miller, F., Guilbaud, O., Dette, H. (2007). Optimal designs for estimating the interesting part of a dose-effect curve. J. Biopharm. Statist. 17:1097-1115.
27. O'Quigley, J. (2001). Dose-finding designs using continual reassessment method. In: Crowley, J., ed. Handbook of Statistics in Clinical Oncology. New York: Marcel Dekker, pp. 35-72.
28. Proschan, M. A., Lan, K. K. G., Wittes, J. T. (2006). Statistical Monitoring of Clinical Trials. A Unified Approach. New York: Springer.
29. Rao, C. R. (1973). Linear Statistical Inference and Its Applications. 2nd ed., New York: Wiley.
30. Ratkowsky, D. A. (1990). Handbook of Nonlinear Regression Models. New York: Marcel Dekker.
31. Ratkowsky, D. A., Reedy, T. J. (1986). Choosing non-linear parameters in the four-parameter logistic model for radioligand and related assays. Biometrics 42:575-582.
32. Rosenberger, W. F., Hughes-Oliver, J. M. (1999). Inference from a sequential design: proof of conjecture by Ford and Silvey. Stat. Prob. Lett. 44:177-180.
33. Rosenberger, W. F., Haines, L. M. (2002). Competing designs for phase I clinical trials: a review. Statist. Med. 21:2757-2770.
34. Whitehead, J., Zhou, Y., Mander, A., Ritchie, S., Sabin, A., Wright, A. (2006). An evaluation of Bayesian designs for dose-escalation studies in healthy volunteers. Statist. Med. 25:433-445.